Last week, we announced our financial results for the first nine months of 2025. Galderma achieved record net sales of 3.737 billion USD, representing year-on-year net sales growth of 15.0% at constant currency, driven predominantly by volume growth complemented by favorable mix. Net sales growth for the third quarter was ahead of expectations, in a market with some constrained consumer spending.
The world is transforming at a faster rate than ever. Organizations have no choice but to keep up with the rapidly evolving technologies that are shaping their industries. At Galderma, we advance our category leadership in dermatology by empowering high-performing IT teams that go above and beyond in their work. Working at Galderma means contributing not only to our growth as a company, but also to your own professional success. We offer personalized development opportunities so our talented people can grow their careers and reach their full potential.
Galderma marks the 10th anniversary of our premium medical skincare brand Alastin® by Galderma with the launch of four core products in China, one of the world’s fastest growing aesthetic skincare markets. As the demand for perioperative skincare accelerates, this expansion shows Galderma’s commitment to delivering science-backed products that drive superior outcomes for even more patients.
This September, Galderma launched a transformative skincare segment with Cetaphil’s new Skin Activator Hydrating & Firming Line, in partnership with actor and filmmaker Mariska Hargitay. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning and fragile skin.
This summer, Galderma announced the launch of the Cetaphil Nourishing Oil to Foam Cleanser, a first-of-its-kind formula designed to deeply cleanse while preserving hydration and supporting the sensitive skin’s moisture barrier. Developed with dermatologists and brought to life through a vibrant team of medical experts and content creators, the cleanser sets a new standard for a gentle-yet-effective, hydrating cleanse.
Galderma has announced the establishment of its new U.S. headquarters in Miami, Florida, positioning the company at the heart of a thriving market for Dermatological Skincare and Injectable Aesthetics. Located in the vibrant Brickell neighborhood, the company expects to have approximately 150 employees, including U.S. leadership roles, based there by 2028.
In a new episode of Galderma’s video interview series Beauty x Medicine, we meet Dr. Jean Carruthers, a.k.a. ‘the godmother of cosmetic dermatology.’ She talks to our CEO, Flemming Ørnskov, MD, MPH, about key learnings from her extraordinary career: the importance of listening to patients, how she convinced peers and patients to embrace her groundbreaking treatment, and how exciting innovations continue to reshape the injectable aesthetics field.
Galderma recently launched the Alastin Skincare Restorative Skin Complex with Next Generation TriHex Technology®: a newly enhanced daily rejuvenating serum designed to support collagen production while addressing visible volume loss.
Phase III trial results for the first and only ready-to-use liquid form of RelabotulinumtoxinA, created using Galderma’s proprietary PEARL(TM) technology, were recently published in Aesthetics Surgery Journal. The results showed high patient-assessed efficacy and satisfaction in the treatment of glabellar (frown) lines. The product has been approved in 15 European countries, with launches ahead of schedule in early 2025.
Galderma received U.S. FDA for its novel biologic treatment for patients with moderate-to-severe atopic dermatitis.
